Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) FCF Margin (2017 - 2025)

Akebia Therapeutics (AKBA) has disclosed FCF Margin for 9 consecutive years, with 53.9% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 6351.0% to 53.9% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 28.66% through Dec 2025, up 5407.0% year-over-year, with the annual reading at 28.66% for FY2025, 5407.0% up from the prior year.
  • FCF Margin for Q4 2025 was 53.9% at Akebia Therapeutics, up from 47.69% in the prior quarter.
  • The five-year high for FCF Margin was 69.39% in Q3 2022, with the low at 7781.73% in Q2 2022.
  • Average FCF Margin over 5 years is 802.25%, with a median of 23.73% recorded in 2025.
  • The sharpest move saw FCF Margin tumbled -766240bps in 2022, then skyrocketed 778816bps in 2023.
  • Over 5 years, FCF Margin stood at 5234.0% in 2021, then soared by 65bps to 1822.63% in 2022, then surged by 99bps to 17.05% in 2023, then skyrocketed by 44bps to 9.61% in 2024, then surged by 661bps to 53.9% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 53.9%, 47.69%, and 35.57% for Q4 2025, Q3 2025, and Q2 2025 respectively.